Literature DB >> 29670704

Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.

Chien-Hung Yeh1, Shawn I Walsh1, Arryn Craney1, M Greg Tabor1, Ana-Florina Voica1, Ramkrishna Adhikary1, Sydney E Morris1, Floyd E Romesberg1.   

Abstract

β-Lactam antibiotics, one of the most important class of human therapeutics, act via the inhibition of penicillin-binding proteins (PBPs). The unparalleled success in their development has inspired efforts to develop them as inhibitors of other targets. Bacterial type I signal peptidase is evolutionarily related to the PBPs, but the stereochemistry of its substrates and its catalytic mechanism suggest that β-lactams with the 5S stereochemistry, as opposed to the 5R stereochemistry of the traditional β-lactams, would be required for inhibition. We report the synthesis and evaluation of a variety of 5S penem derivatives and identify several with promising activity against both a Gram-positive and a Gram-negative bacterial pathogen. To our knowledge these are the first 5S β-lactams to possess significant antibacterial activity and the first β-lactams imparted with antibacterial activity via optimization of the inhibition of a target other than a PBP. Along with the privileged status of their scaffold and the promise of bacterial signal peptidase I (SPase) as a target, this activity makes these compounds promising leads for development as novel therapeutics.

Entities:  

Year:  2018        PMID: 29670704      PMCID: PMC5900324          DOI: 10.1021/acsmedchemlett.8b00064

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  42 in total

1.  Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I.

Authors:  Palaniappan Kulanthaivel; Adam J Kreuzman; Mark A Strege; Matthew D Belvo; Tim A Smitka; Matthew Clemens; James R Swartling; Kristina L Minton; Feng Zheng; Eddie L Angleton; Deborah Mullen; Louis N Jungheim; Valentine J Klimkowski; Thalia I Nicas; Richard C Thompson; Sheng-Bin Peng
Journal:  J Biol Chem       Date:  2004-06-01       Impact factor: 5.157

2.  Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.

Authors:  Peter A Smith; Tucker C Roberts; Floyd E Romesberg
Journal:  Chem Biol       Date:  2010-11-24

Review 3.  Redefining penems.

Authors:  Axel Dalhoff; Nebojsa Janjic; Roger Echols
Journal:  Biochem Pharmacol       Date:  2006-01-18       Impact factor: 5.858

Review 4.  Bacterial protein secretion--a target for new antibiotics?

Authors:  C Stephens; L Shapiro
Journal:  Chem Biol       Date:  1997-09

5.  Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one-based human chymase inhibitors.

Authors:  Y Aoyama; M Uenaka; M Kii; M Tanaka; T Konoike; Y Hayasaki-Kajiwara; N Naya; M Nakajima
Journal:  Bioorg Med Chem       Date:  2001-11       Impact factor: 3.641

6.  Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones.

Authors:  Y Aoyama; M Uenaka; T Konoike; Y Hayasaki-Kajiwara; N Naya; M Nakajima
Journal:  Bioorg Med Chem Lett       Date:  2001-07-09       Impact factor: 2.823

7.  Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease.

Authors:  W W Ogilvie; C Yoakim; F Dô; B Haché; L Lagacé; J Naud; J A O'Meara; R Déziel
Journal:  Bioorg Med Chem       Date:  1999-08       Impact factor: 3.641

8.  Evaluation of the type I signal peptidase as antibacterial target for biofilm-associated infections of Staphylococcus epidermidis.

Authors:  Katrijn Bockstael; Nick Geukens; Lieve Van Mellaert; Piet Herdewijn; Jozef Anné; Arthur Van Aerschot
Journal:  Microbiology       Date:  2009-08-20       Impact factor: 2.777

Review 9.  The chemistry and structure-activity relationships of C3-quaternary ammonium cephem antibiotics.

Authors:  A Laws; M Page
Journal:  J Chemother       Date:  1996-02       Impact factor: 1.714

10.  Structural and initial biological analysis of synthetic arylomycin A2.

Authors:  Tucker C Roberts; Peter A Smith; Ryan T Cirz; Floyd E Romesberg
Journal:  J Am Chem Soc       Date:  2007-12-01       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.